Rubén Ciria

Dr. Rubén Ciria


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2021 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
GWGo Wakabayashi
Go Wakabayashi
DCDaniel Cherqui
Daniel Cherqui
DGDavid A. Geller
David A. Geller
MHMohammed Abu Hilal
Mohammed Abu Hilal
GBGiammauro Berardi
Giammauro Berardi
MYMasakazu Yamamoto
Masakazu Yamamoto

10 January 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
GSG. Sapisochin
G. Sapisochin
CLC. Rodríguez de Lope
C. Rodríguez de Lope
MGM. Gastaca
M. Gastaca
JUJ. Ortiz de Urbina
J. Ortiz de Urbina
MSM. A. Suarez
M. A. Suarez
JBJ. Bruix
J. Bruix
A retrospective cohort multicenter study was conducted to analyze the risk factors for tumor recurrence after liver transplantation (LT) in cirrhotic patients found to have an intrahepatic cholangiocarcinoma (iCCA) on pathology examination. We also aimed to ascertain whether there existed a subgroup of patients with single tumors ≤2 cm (“very early”) in which results after LT can be acceptable. Twenty‐nine patients comprised the study group, eight of whom had a “very early” iCCA (four of them incidentals). The risk of tumor recurrence was significantly associated with larger tumor size as well as larger tumor volume, microscopic vascular invasion and poor degree of differentiation. None of the patients in the “very early” iCCA subgroup presented tumor recurrence compared to 36.4% of those with single tumors >2 cm or multinodular tumors, p = 0.02. The 1‐, 3‐ and 5‐year actuarial survival of those in the “very early” iCCA subgroup was 100%, 73% and 73%, respectively. The present is the first multicenter attempt to ascertain the risk factors for tumor recurrence in cirrhotic patients found to have an iCCA on pathology examination. Cirrhotic patients with iCCA ≤2 cm achieved excellent 5‐year survival, and validation of these findings by other groups may change the current exclusion of such patients from transplant programs.

7 February 2015 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
ZMZenichi Morise
Zenichi Morise
RCRubén Ciria
Rubén Ciria
DCDaniel Cherqui
Daniel Cherqui
KCKuo-Hsin Chen
Kuo-Hsin Chen
GBGiulio Belli
Giulio Belli
GWGo Wakabayashi
Go Wakabayashi

1 November 2014 in Journal of Hepatology
Verified
Journal Article
Closed access
JBJavier Briceño
Javier Briceño
MCManuel Cruz-Ramírez
Manuel Cruz-Ramírez
MPMario Prieto-Velasco
Mario Prieto-Velasco
MNMiguel Navasa
Miguel Navasa
JUJorge Ortiz de Urbina
Jorge Ortiz de Urbina
MMManuel de la Mata
Manuel de la Mata

17 November 2020 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
RCRubén Ciria
Rubén Ciria
GBGiammauro Berardi
Giammauro Berardi
FAFelipe Alconchel
Felipe Alconchel
JBJavier Briceño
Javier Briceño
GCGi Hong Choi
Gi Hong Choi
GWGo Wakabayashi
Go Wakabayashi